Scholarlink

Background <p>Heart failure and ventricular remodeling are the major cardiac injuries after myocardial infarction (MI). Sodium‒glucose cotransporter 2 (SGLT2) inhibitors have been shown to be effective at alleviating heart failure and improving patient outcomes and quality of life. However, whether SGLT2 has the same effect on myocardial infarction is unclear. The aim of this study was to elucidate the efficacy and underlying mechanisms of dapagliflozin on the outcome of myocardial infarction.</p> Methods <p>A porcine model of myocardial infarction was established via percutaneous coronary intervention with a balloon-dilated catheter and treated with dapagliflozin (DPG), an SGLT2 inhibitor, for 8 weeks. The biochemical indices of pig blood were determined. M-mode echocardiography was performed to determine cardiac structure and function. HE staining, Masson staining and TUNEL were used to detect myocardial fibrosis and apoptosis. The expression of target proteins in signal transduction pathways was determined by Western blotting.</p> Results <p>DPG treatment ameliorated myocardial hypertrophy and fibrosis and increased collagen synthesis and apoptosis induced by myocardial infarction in pigs. Moreover, DPG inhibited the activation of the TGF-β1 and MAPK signaling pathways.</p> Conclusion <p>DPG can effectively reduce ventricular remodeling and myocardial cell apoptosis after myocardial infarction. DPG inhibits the TGF-β1 and MAPK pathways.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The SGLT2 inhibitor dapagliflozin alleviates ventricular remodeling and apoptosis after myocardial infarction by inhibiting the TGF-β1 and MAPK pathways

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月7日

查看全文
  • Zhen Zhu,
  • Ying Zhang,
  • Zhong Fang,
  • Xin Li,
  • Chao Ma,
  • Qingqing Liu,
  • Qingling Zhang,
  • Wenjing Zhu,
  • Huixian Su,
  • Xiaodong Xu

摘要

Background

Heart failure and ventricular remodeling are the major cardiac injuries after myocardial infarction (MI). Sodium‒glucose cotransporter 2 (SGLT2) inhibitors have been shown to be effective at alleviating heart failure and improving patient outcomes and quality of life. However, whether SGLT2 has the same effect on myocardial infarction is unclear. The aim of this study was to elucidate the efficacy and underlying mechanisms of dapagliflozin on the outcome of myocardial infarction.

Methods

A porcine model of myocardial infarction was established via percutaneous coronary intervention with a balloon-dilated catheter and treated with dapagliflozin (DPG), an SGLT2 inhibitor, for 8 weeks. The biochemical indices of pig blood were determined. M-mode echocardiography was performed to determine cardiac structure and function. HE staining, Masson staining and TUNEL were used to detect myocardial fibrosis and apoptosis. The expression of target proteins in signal transduction pathways was determined by Western blotting.

Results

DPG treatment ameliorated myocardial hypertrophy and fibrosis and increased collagen synthesis and apoptosis induced by myocardial infarction in pigs. Moreover, DPG inhibited the activation of the TGF-β1 and MAPK signaling pathways.

Conclusion

DPG can effectively reduce ventricular remodeling and myocardial cell apoptosis after myocardial infarction. DPG inhibits the TGF-β1 and MAPK pathways.